Please ensure Javascript is enabled for purposes of website accessibility

Why Novavax, Inc. Stock Rose 18.4% in June

By Cory Renauer – Jul 13, 2016 at 3:05PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Continued optimism for its lead vaccine candidate and some post-Brexit bargain shopping lifted the biotech stock.

Image source: Getty Images.

What: Shares of Novavax, Inc. (NVAX -2.88%), a clinical-stage biotech developing novel vaccines, rose 18.4% in June, according to data from S&P Global Market Intelligence. The stock had been rising since the FDA granted its lead candidate a faster review in May. Post-Brexit bargain shopping late last month, rather than any fundamental news, lifted the stock even further last month.

NVAX Chart

NVAX data by YCharts.

So what: In the U.S. alone, respiratory syncytial virus (RSV) results in about 207,000 annual hospital admissions, but there aren't any vaccines available to prevent its spread. Novavax's RSV F Vaccine is getting close to entering this underserved space, with top-line data from a phase 3 trial in adults over 60 years old expected during the present quarter. 

If the results are positive, the company expects to file an application next year. A fast-track designation granted in May means it could receive a green light from the FDA within six months (instead of the usual 10 months) if the application is accepted.

With over 65 million Americans over the age of 60, an approval for this indication alone gives the vaccine potential to pass the $1 billion annual sales mark. Upcoming data that could expand its label to infants via maternal immunization, and further out to children under five years, could push sales over the $6 billion mark.

Now what: With a market cap of about $2 billion at recent prices, Novavax stock could deliver enormous gains, but it's hardly risk-free. During a phase 2 trial with 1,600 patients over 60 years old, 23 receiving RSV F vaccine showed RSV symptoms within a year of dosing, versus 39 patients receiving a placebo. The 41% risk reduction was statistically significant, but with a p-value of 0.041, it was hardly a slam-dunk.

The phase 3 trial with 11,850 similar patients is looking for a more defined set of symptoms within 182 days of dosing, which Novavax insists increase its odds of success. However, if it fails to reach its goal, investors could end up sitting on heavy losses for years while Novavax develops the runners-up in its pipeline: a couple of phase 2 flu vaccine candidates.

Also concerning is the company's intent to market RSV F vaccine on its own. The company ended March with about $434 million in cash, but it lost $75 million in the first quarter alone. Drug launches can be more unpredictable than clinical trials, and building out a sales force isn't cheap. While Novavax has tremendous potential, its investors have plenty to be nervous about in the quarters ahead.

Cory Renauer has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. You can follow Cory on Twitter @TMFang4apples or connect with him on LinkedIn for more healthcare industry insight. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax Stock Quote
$16.54 (-2.88%) $0.49

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.